Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:administeredBy |
oral
|
| gptkbp:ATCCode |
L01EX08
|
| gptkbp:CASNumber |
288383-20-0
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:hasMolecularFormula |
C25H27N5O2
|
| gptkbp:hasUNII |
6L88J3G96A
|
| https://www.w3.org/2000/01/rdf-schema#label |
cediranib
|
| gptkbp:isInvestigationalDrugFor |
gptkb:cancer
|
| gptkbp:IUPACName |
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
|
| gptkbp:mechanismOfAction |
VEGFR tyrosine kinase inhibitor
|
| gptkbp:molecularWeight |
429.51 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL398867
9933476 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea anorexia fatigue hypertension |
| gptkbp:synonym |
gptkb:AZD2171
|
| gptkbp:target |
gptkb:VEGFR-1
gptkb:VEGFR-2 gptkb:VEGFR-3 |
| gptkbp:bfsParent |
gptkb:Astex_Therapeutics
|
| gptkbp:bfsLayer |
6
|